Literature DB >> 23380715

A clinical risk stratification tool for predicting treatment resistance in major depressive disorder.

Roy H Perlis1.   

Abstract

BACKGROUND: Early identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice.
METHODS: Data were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials.
RESULTS: A logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches--a naïve Bayes classifier and a support vector machine, and a random forest model--was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk.
CONCLUSION: Risk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23380715      PMCID: PMC3690142          DOI: 10.1016/j.biopsych.2012.12.007

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  36 in total

1.  Using Bayesian networks to analyze expression data.

Authors:  N Friedman; M Linial; I Nachman; D Pe'er
Journal:  J Comput Biol       Date:  2000       Impact factor: 1.479

2.  Cumulative illness rating scale.

Authors:  B S Linn; M W Linn; L Gurel
Journal:  J Am Geriatr Soc       Date:  1968-05       Impact factor: 5.562

3.  Strengthening clinical effectiveness trials: equipoise-stratified randomization.

Authors:  P W Lavori; A J Rush; S R Wisniewski; J Alpert; M Fava; D J Kupfer; A Nierenberg; F M Quitkin; H A Sackeim; M E Thase; M Trivedi
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

4.  A review of goodness of fit statistics for use in the development of logistic regression models.

Authors:  S Lemeshow; D W Hosmer
Journal:  Am J Epidemiol       Date:  1982-01       Impact factor: 4.897

5.  A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire.

Authors:  M Zimmerman; J I Mattia
Journal:  Arch Gen Psychiatry       Date:  2001-08

6.  The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity.

Authors:  M Zimmerman; J I Mattia
Journal:  Compr Psychiatry       Date:  2001 May-Jun       Impact factor: 3.735

7.  Psychosocial functioning in patients with treatment resistant depression.

Authors:  Timothy Petersen; George I Papakostas; Yasmin Mahal; Wendy M Guyker; Erin C Beaumont; Jonathan E Alpert; Maurizio Fava; Andrew A Nierenberg
Journal:  Eur Psychiatry       Date:  2004-06       Impact factor: 5.361

8.  APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.

Authors:  W A Knaus; J E Zimmerman; D P Wagner; E A Draper; D E Lawrence
Journal:  Crit Care Med       Date:  1981-08       Impact factor: 7.598

9.  The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Authors:  A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

10.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Authors:  A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe
Journal:  Control Clin Trials       Date:  2004-02
View more
  50 in total

1.  Recent Findings of the Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder: Do We Now Know What to Prescribe?

Authors:  Matthew V Rudorfer
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

2.  Toward precision medicine for depression: admitting ignorance and focusing on failures.

Authors:  A John Rush
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

Review 3.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

4.  Clinical predictors of ketamine response in treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

5.  The role of GRIK4 gene in treatment-resistant depression.

Authors:  Elena Milanesi; Cristian Bonvicini; Chiara Congiu; Marco Bortolomasi; Giulio Gainelli; Massimo Gennarelli; Alessandra Minelli
Journal:  Genet Res (Camb)       Date:  2015-07-03       Impact factor: 1.588

6.  Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Authors:  James W Murrough; Katherine E Burdick; Cara F Levitch; Andrew M Perez; Jess W Brallier; Lee C Chang; Alexandra Foulkes; Dennis S Charney; Sanjay J Mathew; Dan V Iosifescu
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

7.  Rare copy number variation in treatment-resistant major depressive disorder.

Authors:  Colm O'Dushlaine; Stephan Ripke; Douglas M Ruderfer; Steven P Hamilton; Maurizio Fava; Dan V Iosifescu; Isaac S Kohane; Susanne E Churchill; Victor M Castro; Caitlin C Clements; Sarah R Blumenthal; Shawn N Murphy; Jordan W Smoller; Roy H Perlis
Journal:  Biol Psychiatry       Date:  2014-01-19       Impact factor: 13.382

8.  Pretreatment brain states identify likely nonresponse to standard treatments for depression.

Authors:  Callie L McGrath; Mary E Kelley; Boadie W Dunlop; Paul E Holtzheimer; W Edward Craighead; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2013-12-19       Impact factor: 13.382

9.  The Importance of Calibration in Clinical Psychology.

Authors:  Oliver Lindhiem; Isaac T Petersen; Lucas K Mentch; Eric A Youngstrom
Journal:  Assessment       Date:  2018-02-19

10.  Identifying a clinical signature of suicidality among patients with mood disorders: A pilot study using a machine learning approach.

Authors:  Ives Cavalcante Passos; Benson Mwangi; Bo Cao; Jane E Hamilton; Mon-Ju Wu; Xiang Yang Zhang; Giovana B Zunta-Soares; Joao Quevedo; Marcia Kauer-Sant'Anna; Flávio Kapczinski; Jair C Soares
Journal:  J Affect Disord       Date:  2016-01-01       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.